Pipeline Previews

In the same study, 98% of patients treated with Restylane^® Silk reported a visible improvement in the fullness of their lips 14 days after injection and 76% reported that they still had lip improvement at six months following injection.

Restylane^® Silk is administered by a physician or qualified healthcare professional. The product is injected into a patient's lip and/or area around the mouth in one or two sessions as needed and the process typically takes less than one hour. In the clinical study, the results of Restylane^® Silk lasted approximately 6 months following treatment. The most common side effects observed following treatment with Restylane^® Silk were: swelling, tenderness, bruising, pain and redness. The majority of these side effects were mild and decreased in severity within 2-7 days. These side effects have also been observed in other lip enhancement clinical trials.

Treatment volume should be limited to 1.5 mL per lip per treatment and 1.0 mL for perioral rhytid correction, as greater amounts significantly increase moderate and severe injection site reactions.

L’Oréal announced today the extension of the closing date of its International Awards for Social Responsibility in Dermatology to April 15^th 2015.

Patients with dermatological conditions may frequently face discrimination and feel socially excluded, even children. The International Awards for Social Responsibility in Dermatology, “Caring to Inspire Skin Confidence” aim to acknowledge and celebrate the often unseen efforts and hard work carried out by dermatologists worldwide: all their voluntary dermatological initiatives that improve patients’ physical and psychological health and self-esteem, independently from their medical treatment.

L’Oréal created an independent Steering Committee of 7 worldwide renowned dermatologists, who will evaluate each initiative and select five winners, one per major geographical zone: Asia-Pacific, Africa and the Middle East, Europe, North America, and Central-South America.

These awards are supported by the International League of Dermatological Societies (ILDS) and by the 23^rd World Congress of Dermatology and the Awards Ceremony will be held at the 23^rd World Congress of Dermatology in Vancouver, Canada, on June 9, 2015.

First Derm, a dermatology question-and-answer app that is available in the Apple AppStore and Google Play Store, has reached 100,000 downloads.

The app launched a little more than a year ago: January 2014.

First Derm allows users to anonymously take pictures of external skin problems and send them to a licensed dermatologist, who will respond to inquiries within 24 hours of receiving the pictures with an assessment of the problem. App users are asked to send two pictures — one close up and another farther away — along with a description of the skin condition. The consultation costs $40 for each case submitted for assessment.

Users do not have to make an account or register to use the app. First Derm aims to keep all user information anonymous. Another addition to the app is its geo-location abilities that allow a user to locate the nearest pediatrician, dermatologist or pharmacy.

“The main focus is to triage the right patient at the right time to the right level of healthcare,”Alexander Borve, the CEO of First Derm parent company iDoc24, told MobiHealthNews when the app launched last year. “We have an international network of dermatologists, working in five different languages. They have been vetted by our advisory board. Around 20 percent of cases are audited every month to keep a high standard.”

Kythera Biopharmaceuticals Inc. said that the Food and Drug Admnistration advisory panel voted unanimously to recommend approval of the company’s injectable drug ATX-101 to treat adult submental fat, or what is commonly known as a double chin.

The treatment would be a nonsurgical option for double chin, which the company calls a much-cited but undertreated aesthetic complaint that results in an older and heavier facial appearance.

A new non-profit council has recently formed with a mission to finally rid the world’s operating environments of surgical smoke plume once and for all. With the participation of key clinical stakeholders, clinician based organizations, industry partners, and standard setting bodies, this new consensus body is known as the International Council on Surgical Plume (ICSP). The charter of this Council is to provide education, aid in the creation of new clinical studies, drive regulatory reform, and advocate enforcement of existing mandates related to surgical plume throughout the world.

With the formation of the ICSP, surgical stakeholders can join in one voice to advocate for clearer mandates, better dissemination of existing studies, construct meaningful new studies that resonate with those not yet advocating for plume management, and review of new and existing clinical information for scientific credibility.